<DOC>
	<DOCNO>NCT00293592</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind trial , compare clinical outcome administration high-dose dexamethasone versus placebo patient undergoing heart surgery use cardiopulmonary bypass . The primary endpoint occurrence major complication ( include all-cause mortality , myocardial infarction , stroke , renal failure , prolong mechanical ventilation ) first 30 day surgery .</brief_summary>
	<brief_title>Dexamethasone Cardiac Surgery Trial</brief_title>
	<detailed_description />
	<mesh_term>Postoperative Complications</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Systemic Inflammatory Response Syndrome</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>All type cardiac surgery cardiopulmonary bypass use Age 18 year Lifeexpectancy &lt; 6 month Emergency operation Reoperations within admission</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Heart surgery</keyword>
	<keyword>Cardiopulmonary bypass</keyword>
	<keyword>Systemic Inflammatory Response Syndrome ( SIRS )</keyword>
</DOC>